CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 4132
Citations: Bibtex RefMan EndNote GB/T7714
Yang GAO, Fei GAO, Jimin SHI, Huarui FU, He HUANG, Yanmin ZHAO. Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation[J]. Journal of Zhejiang University Science B, 2021, 22(8): 695-700.
@article{title="Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation",
author="Yang GAO, Fei GAO, Jimin SHI, Huarui FU, He HUANG, Yanmin ZHAO",
journal="Journal of Zhejiang University Science B",
volume="22",
number="8",
pages="695-700",
year="2021",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2000532"
}
%0 Journal Article
%T Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation
%A Yang GAO
%A Fei GAO
%A Jimin SHI
%A Huarui FU
%A He HUANG
%A Yanmin ZHAO
%J Journal of Zhejiang University SCIENCE B
%V 22
%N 8
%P 695-700
%@ 1673-1581
%D 2021
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2000532
TY - JOUR
T1 - Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation
A1 - Yang GAO
A1 - Fei GAO
A1 - Jimin SHI
A1 - Huarui FU
A1 - He HUANG
A1 - Yanmin ZHAO
J0 - Journal of Zhejiang University Science B
VL - 22
IS - 8
SP - 695
EP - 700
%@ 1673-1581
Y1 - 2021
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2000532
Abstract: Pure red cell aplasia (PRCA) is a well-recognized complication of ABO major mismatched allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence of 10%–20% (
[1]AlvaradoLJ, HuntsmanHD, ChengH, et al., 2019. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood, 133(19):2043-2055.
[2]BaoWL, BusselJB, HeckS, et al., 2010. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood, 116(22):4639-4645.
[3]BathiniS, HoltzmanNG, KokaR, et al., 2019. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol, 94(8):E216-E219.
[4]BuscaA, DellacasaC, GiacconeL, et al., 2018. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 24(8):1765-1770.
[5]DesmondR, TownsleyDM, DumitriuB, et al., 2014. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood, 123(12):1818-1825.
[6]GaoF, ZhouXY, ShiJM, et al., 2020. Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. Ann Hematol, 99(11):2679-2687.
[7]GuentherKL, CherukuPS, CashA, et al., 2019. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol, 73:1-6.e6.
[8]HirokawaM, FukudaT, OhashiK, et al., 2013. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant, 19(7):1026-1032.
[9]OlnesMJ, ScheinbergP, CalvoKR, et al., 2012. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med, 367(1):11-19.
[10]SackettK, CohnCS, Fahey-AhrndtK, et al., 2018. Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. J Clin Apher, 33(1):108-112.
[11]SelleriC, RaiolaA, de RosaG, et al., 1998. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation. Bone Marrow Transplant, 22(6):605-607.
[12]ShahanJL, HildebrandtGC, 2015. Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med, 25(5):342-344.
[13]VlachodimitropoulouE, ChenYL, GarbowskiM, et al., 2017. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 130(17):1923-1933.
[14]YangX, LevisM, 2014. Pulsed-high-dose dexamethasone as a treatment for pure red cell aplasia following ABO-incompatible allogeneic stem cell transplantation. Transfus Med, 24(4):246-248.
[15]ZhaoZ, SunQ, SokollLJ, et al., 2018. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood, 131(21):2399-2402.
[16]ZhidongW, HongminY, HengxiangW, 2012. Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med, 22(4):302-304.
Open peer comments: Debate/Discuss/Question/Opinion
<1>